FindTrial
Sign In

Rindopepimut (CDX-110) with GM-CSF

DRUG2 trials

Sponsors

Celldex Therapeutics

Conditions

Giant Cell GlioblastomaGlioblastomaGlioblastoma With Oligodendroglial ComponentGliosarcomaRecurrent GlioblastomaRelapsed GlioblastomaSmall Cell Glioblastoma

Phase 2

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
CompletedNCT01498328
Celldex TherapeuticsGiant Cell Glioblastoma, Glioblastoma, Glioblastoma With Oligodendroglial Component +4
Start: 2011-12-31End: 2016-05-17Updated: 2020-02-17

Phase 3

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
CompletedNCT01480479
Celldex TherapeuticsGiant Cell Glioblastoma, Glioblastoma, Glioblastoma With Oligodendroglial Component +2
Start: 2011-11-30End: 2016-11-30Updated: 2018-01-16

Related Papers

Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005-2022.
2023-01-0112 citations
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.
2020-02-07134 citations
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
2017-08-23820 citations
ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma (retracted)
CNS Oncology2015-12-1525 citations
ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.
Journal of Clinical Oncology2015-05-2073 citations
Development of algorithms for a quantitative real time-PCR assay to determine EGFRvIII status in glioblastoma patients from rindopepimut clinical trials.
Journal of Clinical Oncology2015-05-20